Skip to main content

Table 1 Characteristics of subjects included in the study

From: Circulating miR-200c and miR-141 and outcomes in patients with breast cancer

Characteristic

Patients

Controls

 
 

n = 57 (%)

n = 20 (%)

 

Age (years, mean ± SD)

55.4 ± 12.8

54.8 ± 14.3

0.853*

<55

28 (49)

12 (60)

0.48**

≥55

29 (51)

8 (40)

 

Menopause

   

Pre-menopausal

24 (42.1)

N/A

 

Post-menopausal

33 (57.9)

N/A

 

Histology

   

Ductal

50 (87.7)

  

Lobular

5 (8.8)

  

Other

2 (3.5)

  

Histological grade

   

1

7 (12.3)

  

2

25 (43.9)

  

3

23 (40.4)

  

TNM Stage

   

I

14 (24.6)

  

II

13 (22.8)

  

III

17 (29.8)

  

IV

13 (22.8)

  

Lymph nodes involved

   

No

20 (35.1)

  

Yes

37 (64.9)

  

Hormonal Receptors

   

Positive

42 (73.7)

  

Negative

14 (24.6)

  

HER2

   

Positive

14 (24.6 )

  

Negative

42 (73.7 )

  

MIB1

   

<25%

40 (70.2)

  

>25%

14 (24.6)

  

Type

   

Luminal

32 (56.1)

  

HER2

14 (24.6)

  

Triple negative

10 (17.5)

  

R0

28 (49.1)

  

R2

29 (50.9)

  
  1. Abbreviation: ECOG Eastern Cooperative Oncology Group performance status. Residual Status (R): R0, no residual tumour; R2, macroscopic residual tumour. The number (percentages) of patients with data avalaible is indicated. *Student t-test. **Chi2 test.